menu
    • menu
    [{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Not Applicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Not Applicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Termination","leadProduct":"Calcifediol","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Vifor","highestDevelopmentStatusID":"12","companyTruncated":"OPKO Health \/ Vifor"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended-Release Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Not Applicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Extended-Release Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Not Applicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Vifor Fresenius Medical Care Renal Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Vifor Fresenius Medical Care Renal Pharma","highestDevelopmentStatusID":"12","companyTruncated":"OPKO Health \/ Vifor Fresenius Medical Care Renal Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Calcifediol Anhydrous

    Menu

    Calcifediol Anhydrous

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Vifor Fresenius Medical Care Renal Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

                            Details : RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

                            Brand Name : Rayaldee

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 03, 2022

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Vifor Fresenius Medical Care Renal Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 ...

                            Details : RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a...

                            Brand Name : Rayaldee

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2021

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 ...

                            Details : Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact ...

                            Brand Name : Rayaldee

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2021

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : CSL Vifor

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor

                            Details : OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.

                            Brand Name : Rayaldee

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 24, 2021

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : CSL Vifor

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients

                            Details : The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).

                            Brand Name : Rayaldee

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2020

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            OPKO Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients

                            Details : The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 01, 2020

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth